Key result
Interferon beta treatment was not associated with reduced disability progression compared to placebo in patients with primary progressive multiple sclerosis (RR 0.89; 95% CI 0.55-1.43).
Why the study?
Does interferon beta reduce disease progression in patients with primary progressive multiple sclerosis?
Population
123 patients with primary progressive multiple sclerosis (PPMS) pooled from 2 randomized controlled trials
Comparison
Recombinant ss-interferon (interferon beta) vs Placebo
Design
Systematic_review, Randomized, Double or single blind
Authors
Loading...
Does not support interferon beta for disability progression in primary progressive MS; confirms lack of benefit and directs research to alternative targets.
Systematic Review (n=123)
Double or single blind
Randomized
No
Does interferon beta reduce disease progression in patients with primary progressive multiple sclerosis?
Relative Risk: 0.89 (95% CI 0.55–1.43)
Current limited evidence from small trials does not show a significant benefit of interferon beta in reducing disability progression for patients with primary progressive multiple sclerosis.
Rojas et al. (2010) conducted a systematic review in Primary progressive multiple sclerosis (PPMS) (n=123). ss-interferon vs. Placebo was evaluated on Proportion of patients with progression of the disease (RR 0.89, 95% CI 0.55-1.43). Interferon beta treatment was not associated with reduced disability progression compared to placebo in patients with primary progressive multiple sclerosis (RR 0.89; 95% CI 0.55-1.43).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: